Search
loracarbef (Lorabid)
Tradename: Lorabid. 2nd generation cephalosporin.
Indications:
- bacterial infections due to susceptible organisms
- acute otitis media
- upper respiratory tract infections
- tonsillitis
- lower respiratory tract infections
- bronchitis
- pneumomia
- chronic pyelonephritis
- skin or soft tissue infection
Dosage: 200-400 mg PO BID.
Children: Otitis 30 mg/kg/day divided BID. Other 15 mg/kg/day.
Tabs: 200 mg, Suspension: 100 mg/5 mL.
Antimicrobial activity:
Gram positive
- Streptococcus
- Streptococcus group A
- Streptococcus group B
- Streptococcus group C
- Streptococcus group G
- Streptococcus pneumonia
- Streptococcus viridans, milleri
- Staphylococcus aureus (MSSA)
- Staphylococcus epidermidis (+/-)
Gram negative
- Neisseria gonorrhoeae
- Neisseria meningitidis
- Moraxella catarrhalis
- Haemophilus influenzae
- Escherichia coli
- Klebsiella species
- Proteus mirabilis
Interactions
drug interactions
drug adverse effects of cephalosporins
General
cephalosporin, 2nd generation
Properties
MISC-INFO: elimination route KIDNEY
pregnancy-category B
safety in lactation ?
Database Correlations
PUBCHEM correlations
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Sanford Guide to antimicrobial therapy 1997
- Deprecated Reference